- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT03019913
Evaluation of Bedside Methods to Measure Muscularity in Critically Ill Patients
Evaluation of Bedside Methods to Measure Muscularity in Critically Ill Patients: A Prospective Observational Study
Muscle wasting is a significant problem in critically ill patients, with reported losses of a half to three percent per day over the first ten days (for an average 70kg person this equates to 3 to 20kg of muscle loss). Low skeletal muscle mass at admission to the intensive care unit (ICU) and the loss of lean tissue have been associated with negative clinical outcomes, including increased incidence of infections, length of stay, mortality and muscle weakness. It is therefore crucial that technology is utilised to: 1) identify ICU patients with low muscularity on admission, 2) to help understand the factors impacting muscle loss and to 3) assess the effectiveness of interventions aimed at maintaining skeletal muscle mass in this population.
The measurement of lean body mass in patients admitted to the ICU is challenging however, due to the large fluid shifts that occur in this population and logistical issues in moving patients to specialised machinery for body composition analysis. Currently, there is no validated method for accurately assessing a patient's muscle mass at the bedside in the intensive care setting. It is therefore important to investigate the accuracy, feasibility and reliability of bedside methods such as subjective physical assessment of muscle mass, mid arm muscle circumference, ultrasound and bioimpedance analysis to assess muscularity in this population who are primarily bedbound. In order to do this, a critical comparison is required between these methods and muscularity assessed by a "reference" body composition method, such computed tomography (CT) image analysis. Briefly, quantification of skeletal muscle at the abdomen area utilising abdominal CT images has been shown to be highly representative of whole body skeletal muscle volume.
We wish to conduct a pilot, feasibility study (n= 50), which will recruit patients who have a CT scan (containing abdomen area), performed for clinical purposes. Our primary aim will be to investigate whether muscularity assessed with non-invasive bedside methods (ultrasound, bioimpedance analysis, SGA physical assessment, mid arm muscle circumference) are correlated with skeletal muscle mass quantified by a "reference method" (CT image analysis).
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Aim Our primary aim is to investigate whether muscularity assessed via bedside ultrasound is correlated with a reference method for estimating whole body skeletal muscle mass (CT image analysis) in the first few days of critical illness.
Our secondary aims are
- To investigate whether muscularity assessed via other bedside methods (bioimpedance spectroscopy, subjective physical assessment and mid arm muscle circumference) are correlated with a reference method for estimating whole body skeletal muscle mass (CT image analysis) in critically ill patients.
- To better understand the association between measured resting energy expenditure and muscularity in the critically ill.
- To observe changes in skeletal muscle mass (in a sub set of patients who have two CT scans) and the impact various factors, including energy and protein delivery has on these changes.
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
Victoria
-
Melbourne, Victoria, Australien, 3004
- The Alfred Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Have had a CT scan of the L3 vertebra performed for clinical reasons ≤24 hours before or ≤72 hours after ICU admission
Exclusion Criteria:
- CT scan performed >48hrs ago
- Death is imminent or deemed highly likely in the next 96 hours
- Are known to be pregnant
- Treating clinician does not believe the study to be in the best interest of the patient
- It is not possible to image two or more muscle groups via ultrasound (i.e. due to trauma, burns, wounds)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Mean skeletal muscle mass measured by CT scan analysis at L3 area (cm2)
Zeitfenster: CT performed for clinical reasons ≤24 hours before or ≤72 hours after ICU admission
|
CT performed for clinical reasons ≤24 hours before or ≤72 hours after ICU admission
|
Mean skeletal muscle mass measured by ultrasound (muscle thickness at each site, cm and rectus femoris CSA, cm2)
Zeitfenster: <48 hours after CT scan containing L3 area
|
<48 hours after CT scan containing L3 area
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Fat free mass (kg), phase angle and impedance ratio measured by bioimpedance spectroscopy
Zeitfenster: <48 hours after CT scan containing L3 area
|
<48 hours after CT scan containing L3 area
|
Subjective assessment of muscle and fat wasting via SGA (normal, mild-moderate or severe)
Zeitfenster: <48 hours after CT scan containing L3 area
|
<48 hours after CT scan containing L3 area
|
Mid arm muscle circumference (cm)
Zeitfenster: <48 hours after CT scan containing L3 area
|
<48 hours after CT scan containing L3 area
|
Mean skeletal muscle mass measured by CT scan analysis at femoral area (cm2)
Zeitfenster: CT performed for clinical reasons ≤24 hours before or ≤72 hours after ICU admission
|
CT performed for clinical reasons ≤24 hours before or ≤72 hours after ICU admission
|
Measured resting energy expenditure (kilojoules)
Zeitfenster: <48 hours after CT scan containing L3 area
|
<48 hours after CT scan containing L3 area
|
Intramuscular, subcutaneous and visceral adipose tissue CSA at L3 area (cm2)
Zeitfenster: CT performed for clinical reasons ≤24 hours before or ≤72 hours after ICU admission
|
CT performed for clinical reasons ≤24 hours before or ≤72 hours after ICU admission
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Kate Lambell, MNutrDiet, La Trobe University and Alfred Health
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 523/16
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Kritische Krankheit
-
Charite University, Berlin, GermanyReactive Robotics GmbHAbgeschlossenKritische Krankheit | Rehabilitation | Frühe Gehfähigkeit | Critical Illness PolyneuromyopathieDeutschland
-
Adana City Training and Research HospitalAbgeschlossenCritical Illness PolyneuromyopathieTruthahn
-
University of AthensUnbekanntCritical-Illness-Polyneuromyopathie (CIPNM) | Auf der Intensivstation erworbene Schwäche (ICUAW)Griechenland
-
Hospital de Clinicas de Porto AlegreUnbekanntCritical Illness PolyneuropathienBrasilien
-
Charite University, Berlin, GermanyReactive Robotics GmbHAbgeschlossenKritische Krankheit | Covid19 | Rehabilitation | Robotik | Frühmobilisierung | Critical Illness PolyneuromyopathieDeutschland
-
Koç UniversityAbgeschlossenCOVID-19 | Rehabilitation | Akutes Lungenversagen | Erworbene Schwäche auf der Intensivstation | Critical Illness PolyneuromyopathieTruthahn
Klinische Studien zur Observational cohort
-
AstraZenecaAktiv, nicht rekrutierendCOVID-19, SARS-CoV-2Vereinigte Staaten, Belgien, Kanada, Frankreich, Spanien, Dänemark, Thailand, Vietnam, Korea, Republik von, Vereinigtes Königreich, Malaysia, Israel, Taiwan, Australien, Deutschland, Polen, Singapur, Vereinigte Arabische Emirate